A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration

Trial Profile

A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs SER 214 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Serina Therapeutics
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
    • 03 Oct 2017 Planned primary completion date changed from 1 May 2017 to 31 Dec 2017.
    • 25 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top